Kloft C - Search Results

1

Role of TDM-based dose adjustments for taxane anticancer drugs.

Muth M, Ojara FW, Kloft C, Joerger M. Muth M, et al. Among authors: kloft c. Br J Clin Pharmacol. 2021 Feb;87(2):306-316. doi: 10.1111/bcp.14678. Epub 2020 Dec 18. Br J Clin Pharmacol. 2021. PMID: 33247980 Free article. Review.

2

Population pharmacokinetic-pharmacodynamic model for neutropenia with patient subgroup identification: comparison across anticancer drugs.

Kloft C, Wallin J, Henningsson A, Chatelut E, Karlsson MO. Kloft C, et al. Clin Cancer Res. 2006 Sep 15;12(18):5481-90. doi: 10.1158/1078-0432.CCR-06-0815. Clin Cancer Res. 2006. PMID: 17000683

3

Population pharmacokinetic modelling of NS2330 (tesofensine) and its major metabolite in patients with Alzheimer's disease.

Lehr T, Staab A, Tillmann C, Trommeshauser D, Raschig A, Schaefer HG, Kloft C. Lehr T, et al. Among authors: kloft c. Br J Clin Pharmacol. 2007 Jul;64(1):36-48. doi: 10.1111/j.1365-2125.2007.02855.x. Epub 2007 Feb 23. Br J Clin Pharmacol. 2007. PMID: 17324246 Free PMC article. Clinical Trial.

4

Contribution of the active metabolite M1 to the pharmacological activity of tesofensine in vivo: a pharmacokinetic-pharmacodynamic modelling approach.

Lehr T, Staab A, Tillmann C, Nielsen EØ, Trommeshauser D, Schaefer HG, Kloft C. Lehr T, et al. Among authors: kloft c. Br J Pharmacol. 2008 Jan;153(1):164-74. doi: 10.1038/sj.bjp.0707539. Epub 2007 Nov 5. Br J Pharmacol. 2008. PMID: 17982477 Free PMC article.

5

Population pharmacokinetic analysis of a nevirapine-based HIV-1 prevention of mother-to-child transmission program in Uganda to assess the impact of different dosing regimens for newborns.

Frank M, Harms G, Kunz A, Kloft C. Frank M, et al. Among authors: kloft c. J Clin Pharmacol. 2013 Mar;53(3):294-304. doi: 10.1177/0091270012448397. Epub 2013 Jan 24. J Clin Pharmacol. 2013. PMID: 23444284 Clinical Trial.

6

Open-label, randomized study of individualized, pharmacokinetically (PK)-guided dosing of paclitaxel combined with carboplatin or cisplatin in patients with advanced non-small-cell lung cancer (NSCLC).

Joerger M, von Pawel J, Kraff S, Fischer JR, Eberhardt W, Gauler TC, Mueller L, Reinmuth N, Reck M, Kimmich M, Mayer F, Kopp HG, Behringer DM, Ko YD, Hilger RA, Roessler M, Kloft C, Henrich A, Moritz B, Miller MC, Salamone SJ, Jaehde U. Joerger M, et al. Among authors: kloft c. Ann Oncol. 2016 Oct;27(10):1895-902. doi: 10.1093/annonc/mdw290. Epub 2016 Aug 8. Ann Oncol. 2016. PMID: 27502710 Free article. Clinical Trial.

7

Making use of modeling and simulations: Towards individualized tamoxifen therapy in breast cancer .

Klopp-Schulze L, Joerger M, Wicha SG, Parra-Guillen ZP, Kloft C. Klopp-Schulze L, et al. Among authors: kloft c. Int J Clin Pharmacol Ther. 2017 Aug;55(8):690-691. doi: 10.5414/CPXCES15EA05. Int J Clin Pharmacol Ther. 2017. PMID: 27641215 No abstract available.

8

Role of Cytochrome P450 3A4 and 1A2 Phenotyping in Patients with Advanced Non-small-Cell Lung Cancer Receiving Erlotinib Treatment.

Parra-Guillen ZP, Berger PB, Haschke M, Donzelli M, Winogradova D, Pfister B, Früh M, Gillessen S, Krähenbühl S, Kloft C, Joerger M. Parra-Guillen ZP, et al. Among authors: kloft c. Basic Clin Pharmacol Toxicol. 2017 Oct;121(4):309-315. doi: 10.1111/bcpt.12801. Epub 2017 Jun 19. Basic Clin Pharmacol Toxicol. 2017. PMID: 28444958 Free article. Clinical Trial.

9

Exploiting Pharmacokinetic Models of Tamoxifen and Endoxifen to Identify Factors Causing Subtherapeutic Concentrations in Breast Cancer Patients.

Klopp-Schulze L, Joerger M, Wicha SG, Ter Heine R, Csajka C, Parra-Guillen ZP, Kloft C. Klopp-Schulze L, et al. Among authors: kloft c. Clin Pharmacokinet. 2018 Feb;57(2):229-242. doi: 10.1007/s40262-017-0555-z. Clin Pharmacokinet. 2018. PMID: 28540639

10

Semimechanistic Bone Marrow Exhaustion Pharmacokinetic/Pharmacodynamic Model for Chemotherapy-Induced Cumulative Neutropenia.

Henrich A, Joerger M, Kraff S, Jaehde U, Huisinga W, Kloft C, Parra-Guillen ZP. Henrich A, et al. Among authors: kloft c. J Pharmacol Exp Ther. 2017 Aug;362(2):347-358. doi: 10.1124/jpet.117.240309. Epub 2017 Jun 9. J Pharmacol Exp Ther. 2017. PMID: 28600397

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

211 results

Search Page